In this case or if CD19-CAR-T cells do not persist > 6 months after infusion in BCP-ALL (but not for DLBCL), consolidative allogeneic HSCT may be a valid strategy to improve the outcome at the price of chemotoxicity from the conditioning regimen [2,179] and posttransplant complications such as acute and chronic GvHD as well as infectious complications [180]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.